INTRODUCTION
============

Radical prostatectomy (RP) is the definitive treatment for localized prostate cancer \[[@B1],[@B2]\]. Many investigators have reported predictive factors for biochemical recurrence (BCR), such as preoperative prostate-specific antigen (PSA), pathological stage, the Gleason score (GS), and surgical margin status \[[@B3],[@B4]\].

For needle biopsy specimens, both the primary pattern and the highest grade should be added to derive the GS. Unlike needle biopsy, however, it would be misleading to derive the GS by adding the most common Gleason pattern and the highest Gleason pattern on RP specimens. Therefore, in RP specimens, the routine GS consisting of the most prevalent and the second most prevalent architectural patterns should be recorded along with a note stating that there is a tertiary high-grade pattern. It was the consensus of the group that one assigns the GS for a RP specimen on the basis of the primary and secondary patterns with a comment as to the tertiary pattern \[[@B5],[@B6]\].

In RP specimens, GS 7 is the most commonly assigned grade, ranging in frequency from 30% to 50%. GS 7 tumors have been shown to behave significantly worse than tumors with a GS of 6 or less and to have a better prognosis than those with a GS of 8 or more \[[@B7]\]. However, GS 7 tumors have heterogeneous features. Multiple authors have reported differences in recurrence-free survival among patients with Gleason pattern 4+3 and patients with Gleason pattern 3+4 tumors following RP. Chan et al. \[[@B8]\] found that the 5-year actuarial risk of progression was 15% and 40% for Gleason score 3+4 and 4+3 tumors, respectively. Ro et al. \[[@B9]\] revealed that the 5-year BCR-free survival for patients with primary Gleason grades of 3 or 4 was 85.4% and 66.7%, respectively (p\<0.001). Patients with GS 7 tumors and a tertiary Gleason pattern 5 (TGP5) appear to have more advanced pathological features and increased rates of biochemical progression compared with patients without a TGP5 component \[[@B8]\]. In contrast with the above study, TGP5 was not an independent factor for BCR-free survival in patients in the GS 7 and GS 8 groups in another study \[[@B10]\]. However, there are few studies on the characteristics of GS 7 disease with TGP5 after RP \[[@B5]-[@B7],[@B10],[@B11]-[@B17]\]. Thus, we evaluated pathological and oncologic outcomes following RP in patients with GS 7 with TGP5.

MATERIALS AND METHODS
=====================

We retrospectively reviewed the medical records of 310 patients who underwent RP from January 2005 to December 2010. Twenty-four patients who underwent neoadjuvant antiandrogen deprivation (11 patients) or adjuvant antiandrogen deprivation therapy (ADT) or radiation therapy (10 patients) as well as patients with histomorphological post-ADT cancer (2 patients) or pathological stage T0 (1 patient) were excluded. Just 239 (GS 6 to 8) of the remaining 286 patients were included in the study. The patients were classified into four groups: GS 6 (62 patients), GS 7 without TGP5 (132 patients), GS 7 with TGP5 (35 patients), and GS 8 (10 patients).

We analyzed not only preoperative factors such as age, preoperative PSA, total prostate volume, preoperative PSA density (PSAD), digital rectal examination, biopsy GS, percentage biopsy positive cores, and clinical stage, but also postoperative pathological outcomes, including pathological stage, RP GS, percentage tumor volume (%TV), prostatic intraepithelial neoplasia, positive surgical margin (PSM), lymphovascular invasion (LVI), perineural invasion, and BCR.

RP specimens were reviewed by a single experienced pathologist. Pathological examinations were performed by using the whole-mount step-section technique. After the seminal vesicles were removed, the prostate specimens were fixed and serially-sectioned at 3 mm intervals. The pathological stage of RP was determined by using the 2010 TNM classification \[[@B18]\]. Final GS was reviewed according to the 2005 International Society of Urological Pathology (ISUP) Consensus on Gleason grading of prostate cancer \[[@B6]\]. On all slides involved with tumor, the tumor area was marked and the %TV (overall tumor percentage for the entire prostate and percentage tertiary pattern 5 cancer within the tumor) was calculated on the basis of the cumulative percentages of tumor on each slide divided by the number of slides with a significant volume of prostate tissue.

Postoperative follow-up was performed by serum PSA measurements at intervals of 1 to 3 months. BCR was defined as PSA greater than 0.2 ng/mL following an initial postoperative PSA level of less than 0.1 ng/mL \[[@B10]\].

The chi-square test and Mann-Whitney U test were performed to compare the clinical and pathological characteristics between the GS 7 without TGP5 and GS 7 with TGP5 groups. Logistic regression analyses were used for the prediction of pathologic outcomes according to TGP5 in GS 7. The BCR-free survival of each GS group was compared by using the Kaplan-Meier method with the log-lank test. Cox proportional hazards models were used to assess the risk factors of BCR. Statistical analysis was performed with SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA) and statistical significance was defined as a p-value of \<0.05.

RESULTS
=======

Mean follow-up time was 33.7±18.7 months. Of the 239 patients, the number of patients with GS 6, GS 7 without TGP5, GS 7 with TGP5, and GS 8 was 62 (25.9%), 132 (55.2%), 35 (14.5%), and 10 (4.2%), respectively. The comparisons of clinical and pathological characteristics between the GS 7 groups with and without TGP5 are summarized in [Table 1](#T1){ref-type="table"}. PSAD (p=0.022), pathological stage (p=0.037), primary Gleason pattern 4 (p≤0.001), %TV (p= 0.001), presence of PSM (p=0.004), and LVI (p≤0.001) were higher in the GS 7 group with TGP5 than in the group without TGP5.

In logistic regression analyses (after adjustment for age, preoperative PSA, total prostate volume, and digital rectal examination) for prediction of pathologic outcomes, GS 7 with TGP5 was an independent predictor of primary Gleason pattern 4 (p=0.007), %TV larger than 10% (p= 0.011), PSM (p=0.012), and LVI (p≤0.001) ([Table 2](#T2){ref-type="table"}).

Kaplan-Meier survival analysis revealed that the presence of TGP5 in GS 7 was not associated with BCR-free survival (p=0.306). In further subgroup analyses, the BCRfree survival of the group with GS 7 without TGP5 differed from that of the groups with GS 6 and GS 8 (p=0.038 and p=0.008). However, BCR-free survival did not show any significant difference between patients with GS 7 with TGP5 and patients with GS 8 (p=0.120) ([Fig. 1](#F1){ref-type="fig"}). Additionally, in analyses according to the percentage of TGP5, time to BCR was shorter in patients with a higher percentage of TGP5 (≥5%) than in those with a lower percentage of TGP5 (\<5%, 61 months vs. 17 months, p=0.044) ([Fig. 2](#F2){ref-type="fig"}).

In the multivariate analysis for assessment of independent predictors of BCR by use of the Cox proportional hazards model, TGP5 in GS 7 was not a significant predictive factor for BCR (p=0.442). However, PSAD (HR, 3.87; p= 0.006) and PSM (HR, 3.22; p=0.002) were shown to be independent predictors of BCR ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

The GS is an important predictor of BCR and disease-specific survival in men with prostate cancer after definitive treatment \[[@B19]\]. The ISUP Consensus Conference on Gleason Grading on Prostatic Carcinoma decided in 2005 that the GS should include the primary and secondary patterns, with a separate comment on the presence of a tertiary pattern of a higher grade in the RP specimen \[[@B6]\]. Recent studies suggest that the tertiary pattern is significant to pathological outcomes and BCR. A tertiary pattern is observed in 7.5% to 48% of specimens and is associated with BCR \[[@B6],[@B10]-[@B15]\]. In our study, among a total of 239 patients, 167 (70%) had GS 7 tumors and 35 of them (21%) had TGP5 in GS 7, which is comparable to findings in other recent studies.

Our results showed that patients with GS 7 with TGP5 had higher PSAD, pathological stage, GS, %TV, presence of PSM, and LVI than did patients with GS 7 without TGP5. Also, logistic regression analyses revealed that TGP5 in GS 7 was an independent predictor of primary Gleason pattern 4, %TV larger than 10%, PSM, and LVI. The association between the presence of a TGP5 and adverse histopathological features, such as higher GS, pathologic stage, extracapsular extension, LVI, and PSM has been confirmed in several publications \[[@B11],[@B16],[@B17]\]. Interestingly, in terms of correlation between TGP5 and primary Gleason pattern 4, a positive but inverse correlation was reported in previous studies \[[@B7],[@B11],[@B16]\]. Primary Gleason pattern 4 tumors are significantly more likely to contain TGP5 than are tumors with a primary Gleason pattern 3 in GS 7 (Mosse et al., 58% vs 32%; Whittemore et al., 41% vs 10%; and Hattab et al., 41% vs 9%).

In many previous studies, the presence of a tertiary pattern in RP specimens was associated with a higher risk of biochemical failure than that in patients without a tertiary pattern \[[@B5],[@B7],[@B12],[@B13],[@B16],[@B17]\]. Whittemore et al. \[[@B16]\] noted that patients with GS 7 with TGP5 cancer had significantly lower BCR-free survival than did patients with GS 7 cancer (p=0.001). BCR was significantly altered by the presence of a TGP5 in patients with primary Gleason pattern 3 compared with patients with a primary Gleason pattern 4. The overall 5-year BCR-free survival rates for patients with GS 7 tumors and GS 7 with TGP5 tumors were 70% and 40%, respectively. However, Hashine et al. \[[@B10]\] found the 5- and 10-year BCR-free survival rates in the GS 7 group were 78.4% and 75.0%, respectively, among patients with no TGP5 and were 75.4% and 75.4%, respectively, in patients with TGP5. Similarly, our data showed that the presence of TGP5 in GS 7 was not associated with BCR (p=0.306).

In the further subgroup analyses, as for BCR-free survival, there was a considerable difference between patients with GS 6 and those with GS 7 without TGP5 (p=0.038), but no significant difference was found between patients with GS 7 with TGP5 and those with GS 8 (p=0.120). That is to say, a notable finding was that, unlike GS 7 without TGP5, GS 7 with TGP5 had a similar rate of BCR to GS 8. Therefore, the absence of TGP5 does not necessarily mean a better prognosis, but the presence of TGP5 clearly indicates a worse prognosis. These data suggest that GS is an important predictive factor for BCR and that the presence of TGP5 has a potential impact on disease progression.

Pan et al. \[[@B5]\] showed that patients with GS 7 with TGP5 tumors had significantly higher pathological stages and shorter times to BCR than did those with GS 7 tumors but that these variables did not differ statistically from patients with GS 8 tumors. Mosse et al. \[[@B11]\] found that adverse pathological features were significantly associated with GS 7 with TGP5 tumors in patients with primary Gleason pattern 3 compared with patients with primary Gleason pattern 4. Turker et al. \[[@B14]\] revealed shorter BCR-free survival rates for GS \<7 with tertiary Gleason component (TGC) tumors than for GS \<7 tumors without TGC (p\<0.0001) and similar BCR-free survival rates to GS 3+4 tumors. Similarly, GS (3+4) with TGC tumors had shorter BCR-free survival rates than did GS 3+4 tumors without TGC (p=0.001), and GS (4+3)+TGC tumors had shorter BCR-free survival rates than did GS 4+3 tumors without TGC (p=0.04). However, GS (3+4)+TGC, GS (4+3)+TGC, and GS \>7 tumors had similar 5-year BCRfree survival (p\>0.5). Thus, we suggest that TGP5 in GS 7 tumors should always be reported in RP specimens.

There are few published data on the percentage of TGP5. Pan et al. \[[@B5]\] suggested that tertiary TV and volume ratio do not correlate with progression. The results of this analysis did not differ after deleting those cases with a tertiary volume ratio more than 5%. In contrast, we found that time to BCR was shorter in patients with a higher percentage of TGP5 (≥5%) than that in patients with a lower percentage of TGP5 (\<5%, 61 months vs. 17 months, respectively; p=0.044).

In many previous studies, TGP5 in GS 7 was a statistically significant predictor of clinical failure when the analysis was adjusted for pathological stage, surgical margin status, extraprostatic extension, and seminal vesicle invasion \[[@B7],[@B12],[@B14],[@B17]\]. However, multivariate analysis showed that TGP5 was not an independent factor for BCR-free survival in patients in the GS 7 and 8 groups \[[@B10]\]. Similarly, in our study, TGP5 was not a significant predictive factor for BCR (HR, 0.76; p=0.442). However, PSAD (HR, 3.87; p=0.006) and PSM (HR, 3.22; p=0.002) were shown to be independent predictors of BCR in GS 7.

There were some limitations to our study. First, it was based on a relatively small sample size, which consequently lowered the statistical power, especially for the subgroup analyses. Furthermore, because of its retrospective nature, it had the possibility of selection bias, although all of the RP specimens were uniformly reevaluated by an experienced pathologist for this study. This study was based on a relatively short period of time; however, because most BCR occurs within 3 years of surgery, the mean follow-up time was about 3 years and only BCR was assessed. Thus, further research is needed to confirm cancer-specific survival and oncologic outcomes. Despite these limitations, this is the first study to report the significance and characteristics of TGP5 in GS 7 cancer after RP in Korea.

CONCLUSIONS
===========

TGP5 in GS 7 was an independent predictor of primary Gleason pattern 4, %TV larger than 10%, PSM, and LVI. The BCR-free survival of GS 7 with TGP5 was similar to that of GS 8. Also, a higher percentage of TGP5 (≥5%) was associated with a shorter time to BCR in our study. Therefore, TGP5 should be reported in RP specimens. Larger prospective studies are required to assess the predictive value of TGP5 compared with other parameters in predicting the long-term oncologic outcome after RP.
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###### 

Comparisons of clinical and pathological characteristics between Gleason score 7 without and with TGP5
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Values are presented as median (interquartile range) or number (%).

TGP5, tertiary Gleason pattern 5; PSA, prostate-specific antigen; TPV, total prostate volume; PSAD, PSA density; DRE, digital rectal examination; RP, radical prostatectomy; PIN, prostatic intraepithelial neoplasia.

###### 

Logistic regression analyses for prediction of pathological outcomes according to TGP5 in Gleason score 7
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TGP5, tertiary Gleason pattern 5; OR, odds ratio; CI, confidence interval.

^a^:Adjusted for age, preoperative prostate-specific antigen, total prostate volume, and digital rectal examination.

###### 

Multivariate analysis of independent predictors of biochemical recurrence in Gleason score 7
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HR, hazard ratio; CI, confidence interval; PSAD, prostate-specific antigen density.

^a^:Calculated by Cox proportional hazard regression.
